

Table SI. Antibodies used in the present study.

Antibodies	Cat. no.	Dilution	Supplier
HDAC1	ab19845	1:1,000	Abcam
HDAC2 (Y461)	ab32117	1:1,000	Abcam
HDAC3 (Y415)	ab32369	1:1,000	Abcam
CD44	sc-7297	1:1,000	Santa Cruz Biotechnology, Inc.
Ki67	ab92742	1:1,000	Abcam
Bcl-2 (D55G8)	4223s	1:1,000	Cell Signaling Technology, Inc.
Bax	2772s	1:1,000	Cell Signaling Technology, Inc.
Bak (D2D3)	6947S	1:1,000	Cell Signaling Technology, Inc.
Caspase-3	9665s	1:1,000	Cell Signaling Technology, Inc.
Cleaved caspase-3	9664s	1:1,000	Cell Signaling Technology, Inc.
Histone H3 (D1H2)	4499s	1:1,000	Cell Signaling Technology, Inc.
Acetyl-Histone H3 (Lys27) (D5E4)	8173s	1:1,000	Cell Signaling Technology, Inc.
AKT	9272s	1:1,000	Cell Signaling Technology, Inc.
Phospho-AKT (Thr308)	9275s	1:1,000	Cell Signaling Technology, Inc.
MEK1/2 (L38C12)	4694s	1:1,000	Cell Signaling Technology, Inc.
Phospho-MEK1/2 (Ser217/221)	9121s	1:1,000	Cell Signaling Technology, Inc.
p44/42 MAPK (Erk1/2) (137F5)	4695s	1:1,000	Cell Signaling Technology, Inc.
MYCN	9405s	1:1,000	Cell Signaling Technology, Inc.
β -Actin	YM3121	1:2,000	ImmunoWay Biotechnology Company
PTX3	A12669	1:1,000	ABclonal
SOX2	66411-1-IG	1:1,000	Proteintech Group, Inc.
OCT4	11263-1-AP	1:1,000	Proteintech Group, Inc.
BMI-1	66161-1-IG	1:1,000	Proteintech Group, Inc.
Goat anti-rabbit IgG-HRP	sc-2004	1:1,000	Santa Cruz Biotechnology, Inc.
Goat anti-mouse IgG-HRP	sc-2005	1:1,000	Santa Cruz Biotechnology, Inc.

HDAC, histone deacetylase.

Table SII. Primers used in RT-qPCR.

Primer	Sequence (5'-3')
BMI-1-Forward	CCACAGTTTCCTCACATTTC
BMI-1-Reverse	AAGTTGCTGATGACCCATTAC
CD44-Forward	CTGCCGCTTTGCAGGTGTA
CD44- Reverse	CATTGTGGGCAAGGTGCTATT
SOX2-Forward	TGGACAGTTACGCGCACAT
SOX2-Reverse	CGAGTAGGACATGCTGTAGGT
OCT4-Forward	CTTGAATCCCGAATGGAAAGGG
OCT4-Reverse	GTGTATATCCCAGGGTGATCCTC
MYCN-Forward	ACCCGGACGAAGATGACTTCT
MYCN-Reverse	CAGCTCGTTCTCAAGCAGCAT
GAPDH-Forward	CAACGGATTTGGTCGTATTGG
GAPDH- Reverse	TGATGGCAACAATATCCACTTTACC

RT-qPCR, reverse transcription-quantitative PCR.

Table SIII. Association between the HDAC1 expression level and the clinical characteristics of 55 patients with neuroblastoma.

Characteristic	No. of patients	HDAC1 expression		OR	P-value
		Low	High		
All cases	55	23	32		
Sex				0.848	0.790
Male	30	12	18		
Female	25	11	14		
Age				2.685	0.257
<18 months	8	5	3		
≥18 months	47	18	29		
MYCN status				1.288	0.769
Non-amplification	39	17	22		
Amplification	16	6	10		
INSS staging system				2.685	0.257
1, 2, 4s	8	5	3		
3, 4	47	18	29		
COG risk group				5.933	0.056
Low risk	7	4	3		
Moderate risk	6	5	1		
High risk	42	14	28		
LDH (U/l)				6.526	0.149
≤245	5	4	1		
>245	50	19	31		

HDAC, histone deacetylase; OR, odds ratio; INSS, International Neuroblastoma Staging System; COG, Children's Oncology Group; LDH, lactate dehydrogenase.

Table SIV. Association between the HDAC2 expression level and the clinical characteristics of 55 patients with neuroblastoma.

Characteristic	No. of patients	HDAC2 expression		OR	P-value
		Low	High		
All cases	55	40	15		
Sex				0.737	0.764
Male	30	21	9		
Female	25	19	6		
Age				0.800	0.091
<18 months	8	8	0		
≥18 months	47	32	15		
MYCN status				2.000	0.326
Non-amplification	39	30	9		
Amplification	16	10	6		
INSS staging system				0.571	0.669
1, 2, 4s	8	5	3		
3, 4	47	35	12		
COG risk group				0.381	0.999
Low risk	7	5	2		
Moderate risk	6	5	1		
High risk	42	30	12		
LDH (U/l)				0.527	0.606
≤245	5	3	2		
>245	50	37	13		

HDAC, histone deacetylase; OR, odds ratio; INSS, International Neuroblastoma Staging System; COG, Children's Oncology Group; LDH, lactate dehydrogenase.

Table SV. Association between the HDAC3 expression level and the clinical characteristics of 55 patients with neuroblastoma.

Characteristic	No. of patients	HDAC3 expression		OR	P-value
		Low	High		
All cases	55	21	34		
Sex				0.636	0.578
Male	30	10	20		
Female	25	11	14		
Age				0.967	1.000
<18 months	8	3	5		
≥18 months	47	18	29		
MYCN status				15.789	0.002
Non-amplification	39	20	19		
Amplification	16	1	15		
INSS staging system				6.400	0.043
1, 2, 4s	8	6	2		
3, 4	47	15	32		
COG risk group				7.243	0.017
Low risk	7	6	1		
Moderate risk	6	2	4		
High risk	42	13	29		
LDH (U/l)				1.088	0.999
≤245	5	2	3		
>245	50	19	31		

HDAC, histone deacetylase; OR, odds ratio; INSS, International Neuroblastoma Staging System; COG, Children's Oncology Group; LDH, lactate dehydrogenase.

Table SVI. Association between the CD44 expression level and the clinical characteristics of 55 patients with neuroblastoma.

Characteristic		No. of patients	CD44 expression		OR	P-value
			Low	High		
All cases		55	30	25		
Sex					0.360	0.103
Male		30	13	17		
Female		25	17	8		
Age					2.875	0.269
<18 months		8	6	2		
≥18 months		47	24	23		
MYCN status					2.667	0.140
Non-amplification		39	24	15		
Amplification		16	6	10		
INSS staging system					1.467	0.715
1, 2, 4s		8	5	3		
3, 4		47	25	22		
COG risk group					0.966	0.655
Low risk		7	5	2		
Moderate risk		6	3	3		
High risk		42	22	20		
LDH (U/l)					0.524	0.650
≤245		5	2	3		
>245		50	28	22		

OR, odds ratio; INSS, International Neuroblastoma Staging System; COG, Children's Oncology Group; LDH, lactate dehydrogenase.